Outcomes of primary hepatocellular carcinoma treatment: An 8‐year experience with 368 patients in Thailand

Background and Aims : Primary hepatocellular carcinoma (HCC) is common in Thailand and its prognosis is extremely poor. Hepatic resection and liver transplantation are modes of curative therapy and various therapies have been developed to treat inoperable HCC. This study was performed to determine the outcome of therapy and to identify prognostic factors for survival among Thai patients with HCC.

[1]  Zeng-chen Ma,et al.  Clinical evaluation of cryosurgery in the treatment of primary liver cancer Report of 60 Cases , 1988, Cancer.

[2]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[3]  A. Chow,et al.  Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial , 1993 .

[4]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[5]  A. Li,et al.  Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. , 1994, British Journal of Cancer.

[6]  A Morabito,et al.  Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients , 1992, Cancer.

[7]  V. Guinee,et al.  Factors affecting the prognosis of primary liver carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Ensminger,et al.  Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  T. Ravikumar,et al.  A 5-year study of cryosurgery in the treatment of liver tumors. , 1991, Archives of surgery.

[10]  V. Viranuvatti,et al.  Relationship of hepatitis B antigen in cirrhosis and hepatoma in Thailand. An etiological significance. , 1975, Gastroenterology.

[11]  H. Moriwaki,et al.  Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma , 1998, Digestion.

[12]  Y. Shiratori,et al.  Detection of α‐fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: A possible predictor of metastatic hepatocellular carcinoma , 1994, Hepatology.

[13]  A. Liberati,et al.  Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Lok,et al.  Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. , 1989, British Journal of Cancer.

[15]  K. Kotoh,et al.  The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. , 1994, The American journal of gastroenterology.

[16]  O. Matsui,et al.  Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma , 1994, Hepatology.

[17]  R. Chlebowski,et al.  Hepatocellular carcinoma diagnostic and prognostic features in north american patients , 1984, Cancer.

[18]  A. Cnaan,et al.  Prognostic factors for survival in hepatocellular carcinoma. , 1988, Cancer research.

[19]  J. Bruix,et al.  Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients , 1990, Hepatology.

[20]  L. Papoz,et al.  Prognostic factors in patients with hepatocellular carcinoma attempts for the selection of patients with prolonged survival , 1987, Cancer.

[21]  K. Ohnishi,et al.  Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha‐fetoprotein levels. Analysis of 606 patients , 1989, Cancer.